Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Analyzing the Growth Rate of the Cancer Cachexia Market: What’s the Expected CAGR for the Next Decade?

There has been a significant expansion in the heart cancer cachexia market in the past few years. The market, which is projected to rise from $2.47 billion in 2024 to $2.62 billion in 2025, estimates a compound annual growth rate (CAGR) of 6.4%. Factors contributing to this growth during the historical period include an enhanced comprehension of cancer biology, higher cancer rates, an uptick in the elderly population, a stronger emphasis on healthcare centered around the patient, widened treatment alternatives and heightened consciousness among healthcare providers.

In the forthcoming years, the market size for cancer cachexia is slated for a sturdy expansion, with the prognosis pointing to $3.33 billion in 2029 at a compound annual growth rate of 6.2%. Factors driving this incline during the forecast period include heightened awareness of managing cachexia, an aging demographic, the prevalence of innovative treatment methods, increasing healthcare spending, and encouraging government actions. Significant trends within the forecast period encompass the escalation in research and development activities, widening of therapeutic measures, enhancement in diagnosis rates, the uptake of pioneering treatment protocols, and progress in care strategies that offer support.

What Factors Are Propelling the Growth of the Cancer Cachexia Market from 2025 to 2034?

The rise in cancer incidences is anticipated to fuel the expansion of the cancer cachexia market. Cancer is a condition characterized by the uncontrollable division of abnormal cells that form tumors and interfere with ordinary bodily functions. The surge in cancer instances can be linked to numerous factors such as lifestyle alterations, environmental influences, an older generation, genetic susceptibility, enhanced diagnostic techniques for early detection, and increased consciousness that leads more individuals to look for medical consultation. Progress in medical tech and a superior understanding of cancer and its complexities result in more regular diagnosis and reporting of cancer cachexia. Medical professionals are enhancing their capabilities to recognize the symptoms of cachexia, enabling early intervention and the beginning of treatment. For example, in December 2023, the Australian Bureau of Statistics, a governmental statistics agency in Australia, reported that roughly 1.8% of the population, or about 456,200 persons, were diagnosed with cancer in Australia in 2022. Furthermore, in May 2024, the National Cancer Institute, a federal agency in the US, approximated that 2,001,140 new cancer cases will be identified in the US, with a projected death count of 611,720 due to the disease. In 2022, nearly 20 million new cases and 9.7 million deaths associated with cancer occurred globally, which is anticipated to rise to 29.9 million fresh cases and 15.3 million cancer-related deaths by 2040. Thus, the escalating prevalence of cancer is propelling the expansion of the cancer cachexia market.

Request Your Free Cancer Cachexia Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

What Are the Leading Organizations Impacting the Cancer Cachexia Market’s Growth?

Major companies operating in the cancer cachexia market are:

• Pfizer Inc._x000D_

• Merck & Co. Inc._x000D_

• AbbVie Inc._x000D_

• Bayer AG_x000D_

• Sanofi SA_x000D_

What Are the Most Prominent Trends Driving Change in the Cancer Cachexia Market?

Leading firms in the cancer cachexia market are pioneering novel therapies such as monoclonal antibodies for cachexia, with the objective of establishing a specialized treatment for cancer cachexia that improves weight, muscle mass, and the overall lifestyle of patients. The cachexia-specific monoclonal antibody seeks out and suppresses factors inducing muscle and weight reduction. For instance, Pfizer Inc., a pharmaceutical organization based in the US, shared the positive outcome of its Phase 2 study in September 2024 for Ponsegromab, a monoclonal antibody that focuses on GDF-15, undertaken on patients suffering from cancer cachexia. The research exhibited a notable augmentation in weight and enhancements in muscle mass, appetite, and physical activity, with the maximum impact observed from the 400 mg dose. Based on these encouraging results, Pfizer anticipates launching studies in 2025 to delve deeper into the potential benefits of Ponsegromab in treating cancer cachexia.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

What Are the Main Segments of the Cancer Cachexia Market, and How Are They Evolving?

The cancer cachexia market covered in this report is segmented –

1) By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics

2) By Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions

3) By Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies

Subsegments:

1) By Progestogens: Megestrol Acetate, Medroxyprogesterone Acetate, Hydroxyprogesterone Caproate

2) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone

3) By Combination Therapies: Progestogens + Corticosteroids, Progestogens + Anabolic Agents, Corticosteroids + Anabolic Agents

4) By Other Therapeutics: Anabolic Agents, Appetite Stimulants, Anti-inflammatory Drugs, Nutritional Supplements

What Regions Are Leading the Charge in the Cancer Cachexia Market?

North America was the largest region in the cancer cachexia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Cancer Cachexia Market Categorized and Defined in the Industry?

Cancer cachexia is a complex metabolic syndrome characterized by progressive weight loss, muscle wasting, weakness, fatigue, and loss of appetite in individuals with cancer. It is a multifactorial condition resulting from a combination of factors such as inflammation, metabolic abnormalities, and the presence of tumors. Cancer cachexia can significantly impact a patient’s quality of life, impairing their ability to tolerate cancer treatments and reducing their overall survival.

Browse Through More Similar Reports By The Business Research Company:

Appendiceal Cancer Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/appendiceal-cancer-treatment-global-market-report

Breast Cancer Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Bone Cancer Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bone-cancer-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: